BeiGene Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Six dead in 'stampede-like' incident at India temple, ANI says
BeiGene, Ltd. (BGNE) PT Lowered to $427 at Cowen
November 5, 2021 7:15 AM EDTCowen analyst Yaron Werber lowered the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $427.00 (from $441.00) while maintaining an Outperform rating.
The analyst commented, "Revs beat in Q3 ($206M vs. our/cons $183M) due to strength from Brukinsa and Amgen and Celgene product sales.... More
